TESARO (NASDAQ:TSRO)

CAPS Rating: 2 out of 5

Caps

How do you think TSRO will perform against the market?

Add Stock to CAPS Watchlist

All Players

49 Outperform
14 Underperform
 

All-Star Players

15 Outperform
7 Underperform
 

Wall Street

5 Outperform
0 Underperform
 

Top TSRO Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFEBCapital (69.06)
Submitted April 13, 2017

PARP inhibitors could be the next significant class of cancer drugs, and potential label expansion opps and top shelf been-there-done-that management makes this a very intriguing, if also high risk biotech stock to buy.

LazyHarlequin (82.71)
Submitted August 03, 2018

On 8/3/18 down $6.04 to $29.24. Options available for 1/17/20 with strike of $25.00.

TSRO VS S&P 500 (SPY)

TSRO Summary

Recent Community Commentary

Read the most recent pitches from players about TSRO.

Recs

0
Member Avatar pchop12316 (92.99) Submitted: 12/7/2018 10:17:26 AM : Underperform Start Price: $73.72 TSRO Score: -1.13

yes, good move now

Recs

0
Member Avatar Bigsef77 (68.64) Submitted: 11/27/2018 12:52:27 PM : Outperform Start Price: $39.35 TSRO Score: +96.89

Cancer drug company Tesaro shares rise 39% following report that it will explore sale

Tesaro shares soared 39 percent Friday upon a Bloomberg report that the pharmaceutical company will explore the opportunity of a sale.
This comes exactly one week after Tesaro fell more than 20 percent during after-hours trading after the release of drug trial results.
A spokesperson declined to comment.

Tesaro shares soared as much as 39 percent Friday upon a Bloomberg report that the pharmaceutical company will explore the opportunity of a sale.

This comes exactly one week after the cancer drug company fell more than 20 percent during after-hours trading after the release of drug trial results for treatment of small cell lung cancer. A spokesperson declined to comment.

The company is working with financial advisers to examine the deal, and the company could still remain independent, the Bloomberg story said. The financial advisers also have contact other potential buyers.

Tesaro also explored a sale in May 2017, but it did not come to a close. Shares then fell more than 11 percent during that time.

The company was founded in 2010 and went public in 2012. Its first drug, Varubi, was approved by the US Food and Drug Administration in October 2015. It's used to treat chemotherapy side effects, such as nausea and vomiting. It's other cancer drug Zejula has been struggling.

Shares are down 68 percent this year.

This story is developing. Please check back for updates.

Recs

1
Member Avatar LazyHarlequin (82.71) Submitted: 8/3/2018 10:18:01 AM : Underperform Start Price: $29.41 TSRO Score: -157.59

On 8/3/18 down $6.04 to $29.24. Options available for 1/17/20 with strike of $25.00.

Leaderboard

Find the members with the highest scoring picks in TSRO.

Score Leader

efarev

efarev (98.64) Score: +404.55

The Score Leader is the player with the highest score across all their picks in TSRO.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
HDTVBGII 68.29 11/12/2012 Outperform 3W $15.78 +369.01% +91.64% +277.37 0 Comment
orangeandblue2 90.11 11/12/2012 Outperform 5Y $15.96 +363.72% +91.93% +271.80 1 Comment
Shrtstp07 < 20 11/12/2012 Outperform 3Y $15.96 +363.72% +91.93% +271.80 0 Comment
rovi0 61.04 11/9/2018 Outperform 5Y $24.19 +205.95% -4.34% +210.30 0 Comment
jeepdrew222 70.01 8/17/2018 Outperform 5Y $27.31 +171.00% -6.29% +177.29 0 Comment
Playa14 < 20 8/16/2018 Outperform 5Y $27.46 +169.52% -6.14% +175.66 0 Comment
portefeuille2 98.81 4/11/2014 Outperform 5Y $24.48 +202.33% +46.28% +156.05 0 Comment
portefeuille3 96.68 4/11/2014 Outperform 5Y $24.48 +202.33% +46.50% +155.83 0 Comment
NextGenStock < 20 8/23/2018 Outperform 5Y $31.40 +135.70% -6.99% +142.69 0 Comment
gunda7907 < 20 10/1/2014 Outperform 5Y $27.17 +172.40% +35.23% +137.17 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackBMOCapital < 20 1/21/2014 Outperform NS $35.57 +108.07% +44.01% +64.06 0 Comment
trackmizuho < 20 6/25/2013 Outperform NS $31.82 +132.59% +67.84% +64.75 0 Comment
TrackDeutscheSec 84.97 2/6/2013 Outperform NS $18.30 +304.43% +76.71% +227.71 0 Comment
TrackJimCramer 85.24 11/9/2012 Outperform 3W $15.03 +392.42% +92.52% +299.89 0 Comment
TrackCitigroup 90.27 7/23/2012 Outperform NS $14.00 +428.64% +97.81% +330.84 0 Comment

Advertisement